Excel Diagnostics & Nuclear Oncology Center

Houston, Texas 77402

4 studies enrolling now · 8 studies all time

What they study most

Cancer, Glioblastoma Multiforme (GBM), Metastatic Castration-Resistant Prostate Cancer, Neuroendocrine Tumor, Neuroendocrine Tumors, Oncology, Pancreatic Ductal Adenocarcinoma (PDAC), Prostate Cancer, Prostate Cancer (CRPC), Prostate Cancer Metastatic, Prostate Cancer Patients With Bone Metastasis, Solid Tumor

Studies at this site

• Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC) — Recruiting now
• Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 — Recruiting now
• Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients — Running, not enrolling
• Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Running, not enrolling
• MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer — Available (expanded access)
• MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer — Available (expanded access)
• Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer — Completed
• Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®) — Completed